Wed. Jun 23rd, 2021
Neuroblastoma Market

(Albany, US) DelveInsight has launched a new report on “Neuroblastoma Market Insights, Epidemiology, and Market Forecast-2030“.

DelveInsight’s “Neuroblastoma Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Neuroblastoma, historical and forecasted epidemiology as well as the Neuroblastoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the facts:

  • According to DelveInsight, total Incident population of Neuroblastoma in the seven major markets were observed to be more than 1,500 in 2017
  • DelveInsight’s estimate suggest higher incidence of neuroblastoma in the United States, as compared to EU-5 countries and Japan, with 629 Incident population in 2017. Furthermore, the incidence rate of neuroblastoma is increasing at a very slow rate in the United States, has stabilized in the EU5 and in decreasing in Japan for the forecasted period, i.e. 2017–2030.
  • As per DelveInsight’s analyst, among the European countries, France has the highest Incident population of Neuroblastoma with 156 cases, followed by the United Kingdom which has Incident population of 147 in 2017. On the other hand, Spain has the lowest Incident population of 90 cases in 2017.
  • Furthermore, according to DelveInsight’s analyst, Japan witnessed more than 250 incident cases of neuroblastoma in 2017.

Request for free Sample:

Scope of the Report

  • The Neuroblastoma report covers the descriptive overview of Neuroblastoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Neuroblastoma epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Neuroblastoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Neuroblastoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The Neuroblastoma report provides an edge while developing business strategies, by understanding trends shaping and driving the global Neuroblastoma market

Request for free Sample:

Neuroblastoma is an embryonal malignancy of the sympathetic nervous system arising from neuroblasts (pluripotent sympathetic cells). It is derived from two words i.e. “neuro” means nerves and “blastoma” refers to the tumor affecting the immature or developing cells. It originates in the adrenal medulla and paraspinal or periaortic regions where sympathetic nervous system tissue is present.

Stages of neuroblastoma determine the extent of spread of the tumor in the patients, and the disease is staged on the basis of results of physical exams, imaging tests, and biopsies of the main tumor and other tissues. Staging of neuroblastoma is based on two classification systems: International Neuroblastoma Staging System (INSS) and International Neuroblastoma Risk Group Staging System (INRGSS).

Neuroblastoma is most common in very young children, but it is rare in children over the age of 10 years.

Approximately 1% to 2% of patients with neuroblastoma inherit an increased risk of developing neuroblastoma from their parents.

Request for free Sample:

Some of the companies:

  • Y-MABS Therapeutics Inc
  • Autolus Therapeutics
  • Clarity Pharmaceuticals
  • EUSA Pharma
  • United Therapeutics Corp
  • And Many Others

Drugs Covered:

  • Naxitamab
  • Omburtamab
  • Qarziba
  • Unituxin
  • And Many Others

Request for free Sample:

Table of contents:

  1. Key Insights
  2. Executive Summary of Neuroblastoma
  3. Competitive Intelligence Analysis for Neuroblastoma
  4. Neuroblastoma: Market Overview at a Glance
  5. Neuroblastoma: Disease Background and Overview
  6. Patient Journey
  7. Neuroblastoma Epidemiology and Patient Population
  8. Treatment Algorithm, Current Treatment, and Medical Practices
  9. Unmet Needs
  10. Key Endpoints of Neuroblastoma Treatment
  11. Marketed Products
  12. Emerging Therapies
  13. Neuroblastoma: Seven Major Market Analysis
  14. Attribute analysis
  15. 7MM: Market Outlook
  16. Access and Reimbursement Overview of Neuroblastoma
  17. KOL Views
  18. Market Drivers
  19. Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer
  23. About DelveInsight

Request for free Sample:

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

Media Contact
Company Name: 
DelveInsight Business Research LLP
Contact Person: 
Ankit Nigam
Email: [email protected]
New York
United States

By sthakur